Interleukin-1 beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

Gül, AHMET; Tugal-Tutkun, Nuriye; Dınarello, Charles; Reznıkov, Leonid; Esen, BAHAR; Mırza, Amer; Scannon, Patrick; Solınger, Alan

doi:10.1136/annrheumdis-2011-155143

Interleukin-1 beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

Gül A., Tugal-Tutkun I., Dınarello C. A., Reznıkov L., Esen B. A., Mırza A., ...Daha Fazla

ANNALS OF THE RHEUMATIC DISEASES, cilt.71, ss.563-566, 2012 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 71
Basım Tarihi: 2012
Doi Numarası: 10.1136/annrheumdis-2011-155143
Dergi Adı: ANNALS OF THE RHEUMATIC DISEASES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.563-566
İstanbul Üniversitesi Adresli: Evet

Özet

Objective Uveitis and retinal vasculitis are sight-threatening manifestations of Behcet's disease with limited treatment options. This pilot study aimed to evaluate the safety, pharmacokinetics and clinical activity of XOMA 052 (gevokizumab), a recombinant humanised anti-interleukin 1 beta antibody, in Behcet's disease patients with uveitis.